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A B S T R A C T
The prognosis for many patients with acute myeloid leukemia (AML) is poor, mainly due to disease relapse
driven by leukemia stem cells (LSCs). Recent studies have highlighted the unique metabolic properties of LSCs,
which might represent opportunities for LSC-selective targeting. LSCs characteristically have low levels of re-
active oxygen species (ROS), which apparently result from a combination of low mitochondrial activity and high
activity of ROS-removing pathways such as autophagy. Due to this low activity, LSCs are highly dependent on
mitochondrial regulatory mechanisms. These include the anti-apoptotic protein BCL-2, which also has crucial
roles in regulating the mitochondrial membrane potential, and proteins involved in mitophagy.
Here we review the diﬀerent pathways that impact mitochondrial activity and redox-regulation, and highlight
their relevance for the functionality of both HSCs and LSCs. Additionally, novel AML therapy strategies that are
based on interference with those pathways, including the promising BCL-2 inhibitor Venetoclax, are summar-
ized.
1. Introduction and scope of this review
Current treatment strategies for acute myeloid leukemia (AML) re-
sult in an initial reduction of leukemic blasts in the majority of patients.
However, a small population of leukemia stem cells (LSCs) persists
during therapy and leads to disease relapse. In order to improve therapy
success, AML research has focused on studying the molecular me-
chanisms that underlie LSC properties, and highlighted common as well
as distinct features of LSCs compared to normal hematopoietic stem
cells (HSCs). The functionality of HSCs is closely connected to their
ability to avoid accumulation of oxidative stress and maintain low le-
vels of reactive oxygen species (ROS). With increasing levels of ROS,
HSCs capability for long-term repopulation declines, suggesting that
low levels of ROS might be an indicator of stem cell functionality (Hu
et al., 2018; Singh et al., 2018). Several recent studies have supported
the idea that a similar concept applies to LSCs (Jones et al., 2018;
Lagadinou et al., 2013; Pei et al., 2018). LSCs are a relatively rare
fraction of self-renewing malignant cells responsible for disease main-
tenance (Thomas and Majeti, 2017). Interestingly, even though a ROS-
low state is indicative for both HSC and LSC function, the two cell
populations seem to have an altered dependency on pathways
regulating ROS production and mitochondrial health. HSCs rely on
glycolysis as their main energy source, which results in less oxidative
burden compared to mitochondrial oxidative phosphorylation (OX-
PHOS). Mitochondrial activity and ROS production in HSCs are often
induced by either growth factors or cytokines that promote cell dif-
ferentiation or apoptosis. Although LSCs also have characteristically
low levels of OXPHOS (Jones et al., 2018; Lagadinou et al., 2013;
Pollyea et al., 2018a), they depend on this remaining activity for their
survival. Consequently, they ensure low ROS levels and high mi-
tochondrial integrity through mechanisms such as autophagy (Pei et al.,
2018). Moreover, LSCs are highly dependent on pathways that coun-
teract mitochondrial dysfunction and cell death. These LSC-speciﬁc
characteristics led to the hypothesis that LSCs can be selectively tar-
geted during AML treatment while sparing HSCs.
To address this hypothesis, we begin this review by describing mi-
tochondrial ROS generation and removal, and discuss the relevance of
mitochondrial activity for the maintenance and diﬀerentiation of stem
cells. For both HSCs and LSCs we then summarize the current evidence
suggesting that ROS levels are indicative for their functionality. Next,
we describe the signaling pathways that have critical roles in regulating
redox homeostasis and their potential impact on stem cell maintenance.
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This includes ﬁve modes of signaling – HIF-1α, AMPK, mTOR, FOXO
and SIRT – as well as a brief overview of crucial players in DNA damage
response pathways. In the ﬁnal part, we discuss vulnerabilities of LSCs
and how interference with autophagy or the anti-apoptotic protein BCL-
2, which is essential to mitochondrial health, could oﬀer a strategy for
targeting these proteins as part of AML treatment.
2. ROS generation and its relevance for stem cell maintenance and
diﬀerentiation
ROS is a collective term for oxygen-containing molecules that are
more reactive than molecular oxygen (O2), and mainly include hy-
droxyl radicals (OH·), hydrogen peroxide (H2O2) and superoxide anion
radicals (O2·−). Due their chemical characteristics, ROS can easily react
with DNA or RNA bases, fatty acids in lipids or amino acids in proteins
(Ray et al., 2012). For the majority of mammalian cells, mitochondrial
energy production is the major source of ROS (Murphy, 2009). During
ATP production by mitochondrial oxidative phosphorylation (OX-
PHOS), substrates are oxidized by a series of enzyme complexes
(complex I-IV) located at the inner mitochondrial membrane. Reactions
of this electron transport chain (ETC) lead to release of ROS. Besides
ROS production by mitochondria, these molecules are also produced in
enzymatic reactions by the family of nicotinamide adenine dinucleotide
phosphate (NADPH) oxidases (NOXs) and other oxidases involved in
inﬂammatory reactions and other processes. In this review we focus on
the role of mitochondrial ROS.
The total amount of steady-state cellular ROS diﬀers between cell
types. In general, the primitive stem cell fraction has a lower ROS
content during steady-state, while higher ROS levels are found in more
diﬀerentiated cells. This diﬀerence mainly results from metabolic
properties that are closely linked to the cellular function. (Bigarella
et al., 2014). The low ROS content in the stem cell fraction might be
protective for DNA damaging eﬀects (van Galen et al., 2014; Yahata
et al., 2011) and primitive stem cells use various strategies to avoid ROS
generation. For instance, stem cells from diﬀerent origins have been
found to reside in deﬁned anatomical compartments with low oxygen
tension, which are called stem cell niches (Mohyeldin et al., 2010).
These hypoxic conditions induce altered metabolic features, including
characteristically low mitochondrial activity (Rafalski et al., 2012).
Undiﬀerentiated embryonic stem cells contain small, immature mi-
tochondria, but during diﬀerentiation cells acquire a more elongated,
mature mitochondrial phenotype, accompanied by higher copy num-
bers of mitochondrial DNA and elevated ATP production required for
cell growth and proliferation (Facucho-Oliveira and St John, 2009).
Similarly, HSCs were shown to have relatively low mitochondrial ac-
tivity and low membrane potential, a feature that was shown to be
essential for their stemness potential (Maryanovich et al., 2015;
Norddahl et al., 2011; Rimmele et al., 2015; Simsek et al., 2010;
Sukumar et al., 2016; Vannini et al., 2016). Quiescent HSCs rely pri-
marily on anaerobic glycolysis for their energy generation (Suda et al.,
2011). Although this is less eﬃcient than OXPHOS, it also restricts the
burden of ROS-mediated oxidative stress (Fig. 1). However, upregula-
tion of mitochondrial activity in concert with increased ROS levels is
crucial for HSC diﬀerentiation, since disruption of OXPHOS was shown
to impair this process (Takubo et al., 2013; Yu et al., 2013).
ROS can drive cell proliferation and diﬀerentiation mechanistically
via redox modiﬁcation of proteins critically involved in these processes
(Ray et al., 2012). In addition, ROS modulate redox-sensitive factors
that regulate ROS production itself, such as forkhead homeobox type O
family (FOXOs), ataxia telangiectasia mutated (ATM) or Sirtuins
(SIRTs). ROS also modulate molecules that have important functions in
stem cell maintenance, diﬀerentiation or stress response, such as hy-
poxia-inducible factor 1α (HIF-1α), p38 and p53. ROS-mediated acti-
vation of the p38-MAPK (mitogen-activated protein kinase) pathway
was shown to have a crucial role in limiting the lifespan and func-
tionality of HSCs (Ito et al., 2006; Jung et al., 2016; Miyamoto et al.,
2007; Zhang et al., 2016). P38 phosphorylation – and thus activation –
promotes inhibitory programs such as cell-cycle arrest and apoptosis, or
can activate purine metabolism, resulting in increased HSC cycling
(Karigane et al., 2016). Furthermore, ROS-induced p53 was found to be
important for controlling HSC survival (Abbas et al., 2010).
3. ROS-regulating mechanisms maintain HSC functionality
To counteract ROS production and prevent oxidative stress, HSCs
have numerous ROS-scavenging strategies. These include low-mole-
cular-weight reducing peptides (e.g. glutathione, thioredoxin, NADPH),
peroxiredoxins and antioxidant enzymes (e.g. catalase, superoxide
dismutase (SOD), glutathione peroxidase). They also have other ROS
regulating mechanisms, such as mitophagy, that control mitochondrial
quantity and quality (Fig. 1), or the recently discovered process of
CoAlation (Aloum et al., 2019; Tsuchiya et al., 2017). Additionally,
interactions of cells with their microenvironment can impact their ROS
levels (Ludin et al., 2012; Taniguchi Ishikawa et al., 2012). In steady-
state conditions, higher levels of antioxidant enzymes have not been
found in HSCs than in more committed progenitors (Bagger et al.,
2013), indicating that the higher availability of antioxidants does not
explain the lower ROS levels in HSCs. However, transcription factors
regulating the expression of anti-oxidative molecules are essential for
HSC functioning (Jung et al., 2013; Miyamoto et al., 2007; Tothova
et al., 2007; Yalcin et al., 2008). This suggests that stem cells could be
more dependent on anti-oxidative molecules than more committed
progenitors. This postulation is also supported by a recent study
showing a correlation between the magnitude of ROS-mediated eﬀects
and cell size: in smaller cells ROS interact more easily with membranes
(Molavian et al., 2016). Stem cells are characteristically smaller in size
than their progeny (Li et al., 2015) and could thus rely more on ROS-
scavenging mechanisms. In line with this possibility, HSCs were shown
to depend on ROS-regulating pathways such as autophagy, in which
cells break down dysfunctional organelles by lysosomal degradation
(Mizushima et al., 2008).
Autophagy results in the clearance of ROS-producing mitochondria
– a process known as mitophagy –which is especially important for HSC
functioning (Ito et al., 2016; Joshi and Kundu, 2013). Autophagy is
regulated by a number of autophagy-related genes (Atg); Atg5 and Atg7
knock-out mice show an increased number of mitochondria and ROS
levels in hematopoietic stem and progenitor cells in conjunction with
an impaired functionality (Gomez-Puerto et al., 2016; Mortensen et al.,
2011). Similarly, low autophagy levels in aged HSCs are accompanied
by high ROS levels and reduced functionality, whereas aged HSCs with
high autophagy levels perform comparably to their younger counter-
parts (Ho et al., 2017). Eﬃcient mitophagy is also closely linked to the
dynamic mitochondrial fusion/ﬁssion process in which damaged mi-
tochondria become segregated by ﬁssion (division) and healthy mate-
rial is exchanged between mitochondria via fusion. Altered expression
of ﬁssion-proteins DRP1 and FIS1 can impact stem cell maintenance
(Cai et al., 2016; Pei et al., 2018).
4. Excessive mitochondrial ROS production triggers cell death
pathways
Although physiological ROS levels are important for intracellular
signaling, excessive ROS can induce cell death by triggering apoptotic
pathways. Because they are the primary cellular location of ROS pro-
duction, mitochondria are particularly vulnerable to ROS-induced da-
mage. ROS can damage mitochondrial DNA, membrane lipids and
proteins (reviewed in (Cline, 2012)), which can result in mitochondrial
genomic instability and respiratory dysfunction. ROS can also oxidize
and damage components in the inner and outer mitochondrial mem-
brane, resulting in a dysfunctional respiratory chain, a drop in mi-
tochondrial membrane potential and eventually triggering mitochon-
drial permeability transition (MPT) and cell death (Mantel et al., 2015).
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Moreover, accumulation of ROS can induce structural changes in the
mitochondrial outer membrane (MOM) and trigger MOM permeabili-
zation (MOMP) mediated by BCL-2 family proteins. An important ef-
fector of ROS-induced cell death is the pro-apoptotic protein p53.
Whereas mild oxidative stress leads to expression of p53-targets with
antioxidant function, high ROS levels trigger p53-mediated cell death
(Perri et al., 2016). Hyper-activation of p53 was shown to deplete HSCs
(Abbas et al., 2010), whereas drug-induced mitochondrial dysfunction
resulted in LSC-speciﬁc apoptosis in leukemia cells, accompanied by
increased ROS levels and p53-activation.(Guzman et al., 2005) Fur-
thermore, inhibition of autophagy – and thereby mitochondrial turn-
over – was shown to target p53-wildtype leukemias, while being in-
eﬀective on cells carrying p53 mutations (Folkerts et al., 2017). In line
with these observations, several recent studies have shown the im-
portance of mitochondrial health for the survival and function of both
HSCs (Anso et al., 2017; Bejarano-Garcia et al., 2016; Ho et al., 2017;
Hu et al., 2018; Ito et al., 2016; Luchsinger et al., 2016; Mohrin et al.,
2015; Qian et al., 2016; Umemoto et al., 2018) and LSCs (Capala et al.,
2016; Farge et al., 2017; Kuntz et al., 2017; Nguyen et al., 2019b; Pei
et al., 2018; Seneviratne et al., 2019; Yehudai et al., 2018).
Mitochondrial ROS production also plays a central role in a diﬀerent
type of programmed cell death induced by oxidative stress, known as
ferroptosis (Gao et al., 2019), which is the process of regulated necrosis
induced by iron-mediated lipid peroxidation. In brief, if ROS interact
with lipids and remove their free electrons, “lipid ROS” are formed. If
lipid ROS accumulate, ferroptosis-mediated cell death is induced.
5. ROS levels in normal hematopoietic stem cells (HSCs)
It was initially assumed that HSCs have a lower number of mi-
tochondria compared to more diﬀerentiated progenitors, which could
contribute to the low rates of oxidative metabolism observed in HSCs
(Mantel et al., 2012; Mohrin et al., 2015; Romero-Moya et al., 2013;
Takubo et al., 2013; Xiao et al., 2012). However, more recent studies
have challenged this idea by showing that the lower values of
mitochondrial mass observed when using dye-based methods are the
result of an altered expression of eﬄux pumps in HSCs and not of a
lower number of mitochondria. Instead, these researchers proposed that
HSC contain a relatively high number of less active mitochondria (de
Almeida et al., 2017; Norddahl et al., 2011). Notably, the accumulation
of mitochondrial mutations in HSCs did not impair the maintenance of
HSCs per se, but rather their capability to give rise to functional pro-
genitors. This ﬁnding supports the notion that oxidative metabolism is
less important for HSCs themselves, but is crucial for their repopulation
capacity (Norddahl et al., 2011).
Studies that compared ROS levels between stem cells and progenitor
cells found that HSCs and megakaryocyte-erythroid progenitors (MEPs)
have the lowest ROS levels, whereas granulocyte-macrophage pro-
genitors (GMPs) have the highest ROS levels (Khan et al., 2016;
Shinohara et al., 2014). This observation is possibly in line with the
results of several recent studies suggesting that the megakaryocytic
lineage directly evolves from HSCs (Carrelha et al., 2018; Haas et al.,
2015; Notta et al., 2016; Rodriguez-Fraticelli et al., 2018; Sanjuan-Pla
et al., 2013; Yamamoto et al., 2013). Growth factors that promote
myeloid proliferation and diﬀerentiation, as well as cytokines that are
released upon tissue damage (Ishida et al., 2017), often induce mi-
tochondrial biogenesis and ROS production. This correlates with HSC
diﬀerentiation or exhaustion (Hu et al., 2018; Singh et al., 2018).
However, there is still a dynamic range in levels of ROS within the
phenotypically deﬁned steady-state HSC population that is not exposed
to any additional stressors, which is indicative of their functionality. In
2007, Jang and Sharkis separated viable murine Lin−CD45+ bone
marrow cells into a ROS-low and ROS-high fraction based on their
signal intensity for the ﬂuorescent ROS-dye DCFDA (2′,7′-dichloro-
ﬂuorescin diacetate) (Jang and Sharkis, 2007). ROS-low HSCs were
shown to have higher self-renewal potential, whereas serial transplan-
tation assays with ROS-high HSCs exhausted faster than their ROS-low
counterparts due to increased activation of the p38-MAPK. More re-
cently it was shown that TNF secretion by bone marrow cells and
subsequent elevation of ROS can ﬂuctuate between diﬀerent times of
Fig. 1. Steady-state ROS levels vary in the diﬀerent types of hematopoietic cells. Left panel: Hematopoietic stem cells (HSCs) have characteristically low mi-
tochondrial activity and low levels of reactive oxygen species (ROS), which are maintained by using glycolysis as their main energy source, removing stressed (and
ROS producing) mitochondria via autophagy and neutralizing ROS via reactions of anti-oxidative enzymes. HSCs produce less ATP and have less active mitochondria
compared to progenitors. Right panel: More diﬀerentiated progenitors characteristically have higher levels of mitochondrial activity and oxidative phosphorylation
(OXPHOS), increased ATP production and lower levels of autophagy. They also make use of anti-oxidative enzymes to avoid oxidative stress. PRX: peroxiredoxin;
SOD: superoxide dismutase; CAT: catalase; GSH: glutathione; GPX: glutathione peroxidase; GR: glutathione reductase; GSSG: glutathione disulﬁde; NADP: nicoti-
namide adenine dinucleotide phosphate.
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the day based on inﬂuences of light and darkness. This determines
whether HSCs self-renew (when ROS levels are reduced) or diﬀerentiate
(when ROS levels are higher) (Golan et al., 2018). Besides ROS-de-
pendent variability in HSC function during steady state, numerous
mouse gene knock-out studies reported that a stress-induced increase in
ROS results in impaired HSC function or exhaustion (Ito et al., 2004; Liu
et al., 2009; Miyamoto et al., 2007; Tothova et al., 2007). Furthermore,
it was also shown that exposure of HSCs to ambient oxygen during the
procedure of stem cell transplantation can lead to extra-physiologic
oxygen shock/stress response (EPHOSS), resulting in ROS accumulation
and decreased repopulation potential upon transplantation (Mantel
et al., 2015; Woolthuis et al., 2013). In line with this ﬁnding, long-term
engraftment of human HSCs in murine models could be enhanced by
overexpression of catalase (a ROS-detoxifying agent) (Miao et al., 2013)
or pre-treatment with valproic acid, which enhanced glycolytic poten-
tial and decreased mitochondrial activity, thereby counteracting ROS
accumulation (Papa et al., 2018). In summary, these studies indicate
that HSCs are best maintained under ROS-low conditions. During
steady state, these conditions result from their glycolytic metabolism
and location in the hypoxic bone marrow niche.
6. ROS levels in Leukemia stem cells (LSCs)
According to the prevailing LSC model, a rare population of ma-
lignant cells with properties similar to normal HSCs – such as self-re-
newal and quiescence – is capable of maintaining the disease. (reviewed
in (Thomas and Majeti, 2017)). Moreover, LSCs can initiate leukemia
when transplanted into immunodeﬁcient mice (Jordan, 2007), and are
therefore alternatively called leukemia initiating cells (LICs). LSCs are
functionally deﬁned, do not have a uniform phenotype (Eppert et al.,
2011; Sarry et al., 2011) and exhibit great variability in molecular
defects (Shlush et al., 2017). However, despite their heterogeneity,
several recent studies have suggested that LSCs share metabolic features
that are distinct from the total leukemia cell population and char-
acteristically include low mitochondrial activity and low levels of cel-
lular ROS (Hao et al., 2018; Lagadinou et al., 2013; Pei et al., 2018;
Pollyea et al., 2018b).
Recently, Hao et al proposed that LSCs are more glycolytic com-
pared to bulk AMLs cells (Hao et al., 2018), which would reﬂect the
similar relation that HSCs have compared to their more diﬀerentiated
progenitors. The investigators used a metabolic sensor called SoNar
(sensor for NAD(H) redox) that has diﬀerent ﬂuorescent properties
depending on whether it binds to NADH or NAD+, and thus reﬂects the
cytosolic NADH/NAD+ ratio of a cell. Glycolysis describes the con-
version of glucose to pyruvate and leads to production of NADH, which
may be further oxidized to NAD+by mitochondrial reactions or by the
enzyme lactate dehydrogenase during lactate production. Hence, high
levels of glycolysis accompany NADH accumulation, and SoNar-high
cells are assumed to have higher glycolytic activity. SoNar-high cells
were found to be highly enriched for LSCs, in conjunction with low
levels of mitochondrial membrane potential and high expression of
enzymes that block the entry of substrates in the TCA cycle such as the
pyruvate dehydrogenase PDK2.
These ﬁndings are in line with other recent studies showing that
AML LSCs have low levels of oxidative metabolism and reside in the
“ROS-low” fraction of the AML mononuclear cell population
(Lagadinou et al., 2013; Pei et al., 2018; Pollyea et al., 2018b). Ad-
ditionally, our group recently demonstrated that even CD34+ selected
stem- and progenitor AML cells have a relatively broad range of ROS
levels and that the CD34+/ROS-low fraction is enriched for phenotypic
CD34+CD38− LSCs (unpublished results). Low levels of ATP were ob-
served in both SoNar-high and ROS-low cells, but these cells also had
opposing characteristics. In another study, ROS-low leukemia cells were
described as having rather low levels of glycolysis and were enriched
for quiescent cells (Lagadinou et al., 2013), whereas SoNar-high cells
were described as non-quiescent (Hao et al., 2018). However, mice
transplantation studies have indicated that both groups of cells are
enriched for LSCs (Lagadinou et al., 2013), (Hao et al., 2018).
In summary, the above studies suggest that LSCs tend to have low
levels of oxidative metabolism and ROS, which coincides with other
studies demonstrating that overexpression of glycolysis genes such as
PDK2 and PDK3 is associated with poor prognosis in AML (Cui et al.,
2018). Although these observations could lead to the assumption that
LSCs are less dependent on oxidative metabolisms for their survival, the
opposite seems to be the case. Multiple studies have demonstrated that
functional mitochondria biology and OXPHOS are crucial for the sur-
vival and maintenance of leukemia cells (Samudio et al., 2010;
Lagadinou et al., 2013; Cole et al., 2015; Sriskanthadevan et al., 2015).
Inhibition of mitochondrial translation by Tigecycline resulted in de-
creased expression of the mitochondrial complex IV subunits COX-1
and COX-2 and impaired survival of AML LSCs (Skrtic et al., 2011).
Similarly, Tigecycline-treatment eﬃciently targeted primitive CD34+
CML LSCs, whereas it did not aﬀect the colony-forming-capacity of
normal CD34+ cells (Kuntz et al., 2017). When mitochondrial activity
is blocked, LSCs may also have decreased ability to switch to glycolysis
as their main energy source (Lagadinou et al., 2013). Furthermore,
treatment of primary AML blasts with a small molecule inhibitor of
complex I of the mitochondrial electron transport chain (ICAS-010759)
induced apoptosis, while treatment of normal bone marrow cells did
not aﬀect viability (Molina et al., 2018). Additionally, LSC survival was
impaired not only by inhibition of mitochondria themselves, but also by
pathways that generate substrates for the mitochondrial TCA cycle,
including inhibition of fatty acid oxidation (Samudio et al., 2010),
glutaminolysis (Goto et al., 2014) and amino acid metabolism (Jones
et al., 2018).
7. ROS-regulating pathways and their importance for stem cell
functionality
As summarized above, low levels of ROS are indicative for both
HSCs and LSCs. In line with this notion, pathways that contribute to a
cellular ROS-low state are often found to function as guardians of
stemness. These pathways are outlined in this section. Key players for
controlling cellular ROS levels are involved not only in the regulation of
metabolic pathways, but also in important stress response mechanisms
such as DNA repair or autophagy. Furthermore, eﬀective functioning of
pathways that mediate mitochondrial health is essential for both HSC
and LSC functionality (Fig. 2).
7.1. HIF signaling
The transcription factors hypoxia-inducible factor (HIF) 1α and 2α
have key role in translating changes of the cellular environment and
nutrient availability into a transcriptional response. HIF-1α and HIF-2α
both form heterodimers composed of a constitutively-expressed β-sub-
unit and an α-subunit that is degraded by an oxygen-depended hy-
drolase. Consequently, it is present only under hypoxic conditions (Ivan
et al., 2001). HIF-1α was shown to be highly expressed in HSCs with
long-term repopulating capacity (Simsek et al., 2010) and has been
described as a master regulator of metabolic pathways that contribute
to a ROS-low environment (Gezer et al., 2014; Karigane and Takubo,
2017; Zhang and Sadek, 2014). In brief, HIF-1α stimulates glycolysis by
inducing expression of glycolytic enzymes (e.g. HK1, LDHA) and glu-
cose transports (e.g. GLUT1), and inhibits mitochondrial OXPHOS by
inducing expression of enzymes (e.g. PDK2, PDK4) that block entry of
substrates into the TCA cycle.
Although no consensus has been reached on whether HIF expression
is necessary for full functionality of HSCs, multiple studies have in-
dicated that HIF plays a role in HSC function: Conditional deletion of
Hif-1α itself (Takubo et al., 2010) or its upstream regulator Meis1
(Simsek et al., 2010) was shown to impair HSC quiescence. Meis1-/-
HSCs showed increased ROS production, loss of HSC maintenance
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under stress conditions and increased HSC apoptosis, which is a phe-
notype that could be entirely rescued by treatment with NAC (Kocabas
et al., 2012; Unnisa et al., 2012). Furthermore, depletion of the HIF-1α
target gene Ldha, a subunit of the enzyme lactate dehydrogenase (LDH)
that regulates the last step of anaerobic glycolysis, increased ROS levels
in mouse bone marrow and impaired HSC maintenance (Wang et al.,
2014). Similarly, deletion of the HIF-1α target genes Pdk2 and Pdk4 in
murine HSCs impaired HSC transplantation capacity and resulted in
increased levels of ROS and expression of senescence markers (Takubo
et al., 2013). Also, knockdown of the HIF-1-inhibitor CITED2 (CBP/
p300-interacting-transactivator-with-an-ED-rich-tail 2) was shown to
aﬀect HSC maintenance (Du et al., 2012; Korthuis et al., 2015; Kranc
et al., 2009) and result in impaired glycolysis with elevated cellular
ROS levels (Du et al., 2014). This suggests that tight regulation of HIF
levels is crucial for maintaining HSC metabolism.
However, other recent studies reported that individual or combined
deletion of HIF-1 and HIF-2 in HSCs does not aﬀect their self-renewal
and repopulation capacity, also in the context of serial transplantations
or 5-ﬂuorouracil treatment (Guitart et al., 2013; Vukovic et al., 2016,
2015). This disparity in results could be related to diﬀerent experi-
mental designs: Whereas Hif-1α deletion in both murine HSCs and bone
marrow environment aﬀected HSC function (Takubo et al., 2010), Hif-
1α deletion only in the hematopoietic cells did not (Vukovic et al.,
2016). In line with this explanation, a recent study concluded that
stable expression of HIF proteins is less relevant for stem cell main-
tenance itself, but is instead important for eﬀective mobilization of
HSPCs from the bone marrow niche to the peripheral blood (Bisht et al.,
2019). Moreover, other studies have shown that hypoxic conditions can
also inﬂuence ROS levels and that the ROS-signaling network is in a
certain manner independent of HIF (Fortenbery et al., 2018; Naranjo-
Suarez et al., 2012). Therefore, HIF-mediated ROS regulation might not
be fundamental for HSC functionality.
Similarly to HSCs, the role of HIF signaling for LSCs is also not yet
fully understood. A recent study by Raﬀel et al. indicated that enhanced
activity of enzymes that target HIF-1α for degradation can decrease
AML stem cell maintenance (Raﬀel et al., 2017), thus supporting a role
for HIF-1 in LSC function. Similarly, decreased expression of HIF-2α
and CITED2 induced by anti-diabetic drug treatment was suggested as
being involved in CML-LSC elimination (Prost et al., 2015). In contrast,
LSCs lacking both HIF-1α and HIF-2α are still capable of promoting
AML development (Vukovic et al., 2015) and HIF-1α-deleted leukemia
cells showed an even faster disease progression after chemotherapy
(Velasco-Hernandez et al., 2019). Consequently, the role of HIFs in LSCs
and leukemia pathogenesis remains unclear.
7.2. FOXO signaling
Transcription factors of the forkhead box class O (FOXO) family are
important to the oxidative defense machinery and stimulate the ex-
pression of genes coding for antioxidant proteins such as SOD, catalase
and sestrin (reviewed in (Klotz et al., 2015)). FOXO proteins (including
FOXO1a, FOXO3a, FOXO4 and FOXO6 in humans) are normally present
in an active state in the cell nucleus, but are exported to the cytoplasm
upon phosphorylation, frequently by the AKT kinase downstream of the
PI3K-signaling pathway. However, other factors such as the
NAD+dependent deacetylase SIRT1 can also impact the subcellular
localization of FOXOs (Liang et al., 2016; Santo and Paik, 2016). The
family member FOXO3a was shown to be essential for HSC main-
tenance, since Foxo3a-/- HSCs failed to support long-term reconstitu-
tion of hematopoiesis and were accompanied by increased ROS levels,
activated p38 MAPK signaling and defective DNA damage repair
(Bigarella et al., 2017; Miyamoto et al., 2007). FOXOs are also involved
in glucose metabolism by regulating phosphenol-pyruvate carbox-
ykinase (PEPCK) and Glucose-6-phosphatase (G6Pase), two enzymes
involved in gluconeogenesis (Zhang et al., 2018). Intriguingly, Rimmelé
et al. demonstrated that elevated ROS levels observed in Foxo3-/- HSCs
were not the result of a shift from glycolytic towards mitochondrial
metabolism, nor did they have a causative role in impaired HSC func-
tionality (Rimmele et al., 2015). Besides high ROS levels, Foxo3-/- HSCs
had increased glycolysis levels, decreased OXPHOS and were associated
with abnormalities in mitochondrial membrane potential and mass,
indicating an important role of FOXOs for mitochondrial metabolism.
A previous study showed that in-vivo treatment of Foxo1/2/3- triple
knockout mice with NAC could rescue the impaired repopulation ca-
pacity of HSCs in mice transplantation studies when treatment was
continued for 5 weeks (Tothova et al., 2007). However, Rimmelé et al.
showed that a NAC-mediated rescue of dysfunctional Foxo3a-/- HSCs in
repopulation studies was only short-term and was lost at 8 weeks after
transplant, despite sustained lowering of ROS levels (Rimmele et al.,
2015). This indicates that elevated ROS levels in FOXO-deﬁcient HSCs
are not the main cause for their dysfunction; instead, this may reﬂect an
abnormal mitochondrial function. This notion is supported by a study
showing that FOXOs promote mitochondrial integrity by stimulating
autophagy. FOXOs induce upregulation of the enzyme glutamine syn-
thase, which consequently stimulates glutamine production (van der
Vos et al., 2012). High glutamine levels block the mTOR-signaling
pathway, which is a negative regulator of autophagy.
7.3. AMPK signaling pathway
The AMP-activated protein kinase (AMPK) is a master regulator of
ROS production and elimination. Activated AMPK signaling inhibits the
ROS-generating mammalian target of rapamycin (mTOR)- pathway and
activates FOXO signaling, which promotes a ROS detoxifying cascade
and stimulates ULK1-mediated autophagy that helps to remove da-
maged organelles. As its name suggests, AMPK is activated by the
binding of AMP, which thus takes place in conditions where the AMP/
ATP ratio is high. Upstream activators include the kinases LKB1 and
CaMMK. Activation of AMPK by the diabetes drug metformin was
shown to increase ex vivo maintenance of murine HSCs (Liu et al.,
Fig. 2. A crosstalk of signaling pathways determines the ﬁnal ROS concentra-
tion and impacts stemness. Various pathways inﬂuence ROS levels by reg-
ulating mitochondrial activity, glycolysis, autophagy, expression of anti-
oxidative enzymes or stress-responsive signaling cascades. AMPK: AMP-
activated protein kinase; mTOR: mammalian target of rapamycin; FOXO:
forkhead box class O family; ATM: ataxia telangiectasia mutated; hypoxia-in-
ducible factor 1α (HIF-1α); SIRT1: sirtuin 1; p38 MAPK: p38 mitogen activated
protein kinase.
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2015). However, deletion of AMPK in murine HSC only moderately
eﬀected HSC function (Gan et al., 2010; Gurumurthy et al., 2010;
Nakada et al., 2010), potentially highlighting the role of AMPK in HSC
maintenance under certain stress conditions.
In contrast to its function in HSCs, AMPK seems to be more relevant
for the survival of LSCs by protecting them from metabolic stress. AMPK
deletion in AML LSCs was shown to result in increased ROS levels and
DNA damage, as well as reduced glucose ﬂux due to impaired glucose
transporter expression, which signiﬁcantly delayed leukemogenesis
(Saito et al., 2015). Pei et al. (2018) showed that AMPK is intrinsically
activated in LSCs and regulates LSC mitochondrial dynamics, thereby
conferring LSCs with increased resistance to mitochondrial stress. Ad-
ditionally, increased AMPK activation was shown to mediate resistance
of AML cells to certain epigenetic agents by stimulating ULK1-mediated
autophagy (Jang et al., 2017), which potentially protects cells from
accumulation of ROS and oxidative damage and highlights elevated
AMPK signaling as an important survival strategy of LSCs.
7.4. mTOR signaling
AMPK indirectly inhibits the mTOR pathway by phosphorylating –
and thereby activating – tuberous sclerosis complex 2 (TSC2), which is
part of the TSC1-TSC2 complex that inhibits mTOR1. The mTOR sig-
naling pathway is activated when the availability of nutrients and ATP
is high; this pathway promotes anabolic processes like protein synthesis
and mitochondrial activity, but inhibits autophagy. In opposition to
AMPK, the pro-proliferative AKT pathway activates mTOR (reviewed in
(Zhao et al., 2017)). Prevention of mTOR hyper-activation is essential
for preservation of the HSC self-renewal capacity (Jang and Sharkis,
2007). Tsc1 deletion in HSCs was shown to dramatically increase ROS
production and to drive quiescent HSCs into rapid cycling (Chen et al.,
2008), whereas treatment of cultured mouse bone marrow cells with
the mTOR-inhibitor rapamycin preserved HSPCs (Huang et al., 2012).
Furthermore, expression of miRNAs that target the mTOR pathway was
shown to be critical for preserving long-term repopulating HSCs, while
their loss resulted in enhanced mitochondrial biogenesis, metabolic
activity and ROS production in HSCs (Qian et al., 2016).
mTOR promotes mitochondrial activity in multiple ways. First, it
stimulates translation of mitochondria-related genes by phosphor-
ylating eukaryotic translation initiation factor 4E (eIF4E)-binding pro-
teins (4E-BPs), which leads to their dissociation from eIF4E and as-
sembly of the translation initiation complex (Morita et al., 2013). Hypo-
phosphorylation of 4E-BP is characteristic for HSCs and is important for
their functionality (Signer et al., 2016). Second, mTOR stimulates ac-
tivity of the transcriptional regulator PPARγ coactivator-1α (PGC-1α), a
master regulator of mitochondrial metabolism and activator of mi-
tochondrial fatty acid oxidation genes (Cunningham et al., 2007; Hu
et al., 2018). Of note, PGC-1α also stimulates gluconeogenesis and is
induced by stemness-associated genes such as CITED2, highlighting that
diﬀerent pathways can inﬂuence the impact of PGC-1α signaling on
ROS levels in an opposite way (Sakai et al., 2016, 2012). Finally,
mTOR1 phosphorylates and inactivates the pro-autophagic kinase ULK1
(Kim et al., 2011) and thereby inhibits autophagy, resulting in the ac-
cumulation of mitochondria (Ho et al., 2017).
7.5. DNA damage response pathways
Mouse models in which genes are deleted that participate in DNA
damage response frequently show a similar phenotype of dysfunctional
HSCs (reviewed in (Niedernhofer, 2008)). For the genes ATM (ataxia
telangiectasia mutated) and MLL5 (Mixed-Lineage-Leukemia-5), the
phenotype of dysfunctional HSCs lacking their expression has been
proposed to be causally connected to accumulation of ROS (Ito et al.,
2004; Tasdogan et al., 2016). The ATM protein kinase is activated by
DNA double strand breaks and modulates the activity of various targets
to maintain genomic stability by initiating an eﬀective DNA damage
response (Shiloh, 2003). These targets include numerous antioxidant
enzymes that prevent increased ROS levels and oxidative stress (Barzilai
et al., 2002). Ito et al. (2004) showed that increased ROS levels in
Atm-/- HSCs led to an impaired self-renewal capacity, which could be
restored by treatment with anti-oxidative agents. Mechanistically, high
ROS levels in Atm-/- HSCs have been shown to activate the p38 MAPK
pathway and upregulate p16INK4a, which is associated with induction
of HSC senescence (Shao et al., 2011). A comparable observation re-
garding HSC dysfunctionality was made in Mll5-/- mice, which showed
accumulation of DNA damage, ROS-mediated upregulation of
p16INK4a and reversal of the phenotype when treated with the anti-
oxidant NAC (Tasdogan et al., 2016). In summary, defective DNA da-
mage response can result in increased ROS production or impaired ROS
elimination, showing that DNA damage response pathways play a
crucial role in redox homeostasis and HSC maintenance.
7.6. SIRT1 signaling
Sirtuins are a family of NAD+-dependent lysine deacetylases with
seven members in mammals (SIRT1-7), of which SIRT3, SIRT4 and
SIRT5 are localized exclusively within the mitochondria. The activity of
sirtuins can be inﬂuenced by oxidative stress at multiple levels: ROS can
induce posttranslational modiﬁcation, change SIRT expression or pro-
tein-protein interactions, or aﬀect cellular NAD levels (Santos et al.,
2016). The enzymes can be viewed as metabolic sensors in a cell; they
play an important role in mediating cellular stress responses or indu-
cing metabolic changes by regulating the activity of targets such as p53,
FOXOs, E2F1 or PGC-1α (reviewed in (Chalkiadaki and Guarente,
2015)). Increased activation of SIRTs eventually results in elevated
expression of anti-oxidants such as SOD2 and catalase, as well as sti-
mulation of autophagy, thereby reducing cellular ROS. Additionally,
SIRTs promote mitochondrial biogenesis and increased turnover of
mitochondria, thereby stimulating removal of damaged mitochondria
that otherwise would produce excessive ROS.
Several SIRT family members appear to play a crucial role in HSC
functioning under stress conditions. For example, deletion of SIRT1 in
HSCs has been shown to impair HSC homeostasis and to induce an
aging-like phenotype by altered regulation of FOXO3 (Rimmele et al.,
2014). Deletion of SIRT3 was shown not only to be indispensable for
maintenance of young HSCs, but also to be essential under stress con-
ditions or during ageing (Brown et al., 2013). SIRT6 was shown to
regulate HSC function by suppressing Wnt target genes, and deletion of
SIRT6 led to impaired HSC self-renewal ability (Wang et al., 2016).
SIRT1 was found to be consistently overexpressed in AML (Bradbury
et al., 2005), and was associated with increased leukemia cell survival,
proliferation and drug resistance (Kim et al., 2015; Li and Bhatia,
2015), suggesting that SIRT1 also promotes maintenances of LSCs.
Nevertheless, SIRT1 deﬁciency was shown to enhance – and not sup-
press – the maintenance of LSCs from MDS (myelodysplastic syndrome)
patients by leading to decreased activity of the tumor suppressor Tet
methylcytosine dioxygenase 2 (TET2) (Sun et al., 2018), indicating that
SIRTs have distinct, context-dependent functions in HSC/LSC main-
tenance. Furthermore, SIRT2 has been shown to be involved in meta-
bolic reprogramming of leukemia cells by stimulating the pentose
phosphate pathway (Xu et al., 2016), highlighting an important role of
SIRTs in both leukemia proliferation and maintenance via multiple
routes.
8. Strategies for targeting leukemia stem cells
HSCs and LSCs are both characterized by low ROS levels and im-
pairment of various ROS-regulating pathways can inﬂuence both HSC
and LSC function. However, the two populations appear to depend on
diﬀerent pathways to maintain their characteristic redox state or to
prevent them from going into apoptosis. As mentioned earlier, LSCs rely
on mitochondrial integrity and metabolism for their survival, and
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mitochondrial ATP generation is crucial for leukemia progression.
However, due to the altered metabolic properties of LSCs and their
relatively low levels of mitochondrial membrane potential (Hao et al.,
2018; Lagadinou et al., 2013; Lin et al., 2019), they are potentially
more prone to undergo mitochondrial permeability transition (MPT) or
apoptosis (Trotta et al., 2017). Therefore, it is likely that LSCs have an
increased dependence on factors that counteract programmed cell
death or protect them from stress-induced impairment (oxidative or
otherwise) of mitochondrial function, which could provide a window
for leukemia therapy. This concept is supported by multiple recent
studies that reported increased dependency of LSCs on the anti-apop-
totic BCL-2 or on stress-response mechanisms such as autophagy
(Fig. 3), which are be described below in more detail.
8.1. Compromising mitochondrial functionality of ROS-low LSCs by BCL-2
inhibition
BCL-2 can be seen as a master regulator of mitochondrial physiology
and cellular stress response. In its canonical role, BCL-2 functions as an
anti-apoptotic protein by preventing mitochondrial outer membrane
permeabilization (MOMP) via its interaction with the pro-apoptotic
proteins BAX and BAD. However, BCL-2 has also additional functions
that inﬂuence mitochondrial activity and the cellular redox state by
regulating both pro-oxidative and anti-oxidative processes (Chong
et al., 2014; Gross and Katz, 2017). BCL-2 was shown to interact with
the COX Vα-subunit of complex IV that is part of the electron transport
chain (ETC), thereby potentially facilitating the transport of this sub-
unit to the mitochondria and increasing mitochondrial activity (Chen
and Pervaiz, 2010). Furthermore, BCL-2 was found to promote the
transport of the anti-oxidant glutathione to mitochondria via direct
interaction (Zimmermann et al., 2007). In line with this, high levels of
BCL-2 were shown to provide increased resistance against a decline in
membrane potential and MPT induction by maintaining reduced pyr-
idine nucleotides (Kowaltowski et al., 2000). As early as 1993, BCL-2
was shown to function as an anti-oxidant (Hockenbery et al., 1993;
Kane et al., 1993), and later studies demonstrated that BCL-2 over-
expression shifts the redox-state of a cell to a more reduced state
(Ellerby et al., 1996; Nguyen et al., 2019a). Consequently, BCL-2 also
inﬂuences activation of redox-sensitive transcription factors such as NF-
κB, p53, and AP-1-, which have a crucial role in stress response. In
summary, BCL-2 preserves mitochondrial stability by preventing a drop
of the mitochondrial membrane potential by both stimulating mi-
tochondrial activity and functioning as an anti-oxidant that counteracts
the increased ROS production (Fig. 3A).
Campos et al. (1994) showed that BCL-2 inhibition aﬀects the sur-
vival of leukemic stem cells and progenitor cells and improves the ef-
ﬁcacy of chemotherapeutic drugs. More recently, several studies in-
dicated that BCL-2 inhibition eﬃciently targets LSCs (Beurlet et al.,
2013; Carter et al., 2016; Goﬀ et al., 2013; Jones et al., 2018; Lagadinou
et al., 2013; Pollyea et al., 2018b). Lagadinou et al. (2013) reported
that LSCs – which they deﬁned as the fraction of total mononuclear
AML cells with the lowest ROS levels – are especially sensitive to BCL-2
inhibition due to their higher BCL-2 expression compared to their non-
LSC counterparts (Lagadinou et al., 2013). Mechanistically, BCL-2 in-
hibition was found to impair OXPHOS, which is crucial for LSC survival
(Lagadinou et al., 2013; Pollyea et al., 2018a). Additionally, results
from our group indicate that ROS-low CD34+ AML cells are more
sensitive to the BCL-2 inhibitor Venetoclax (Souers et al., 2013) com-
pared to ROS-high CD34+ AML cells despite similar BCL-2 expression
levels (unpublished results), highlighting their increased BCL-2
Fig. 3. LSCs have increased depen-
dence on BCL-2 mediated mitochon-
drial regulation and mitophagy. (A)
BCL-2 regulates mitochondrial function
mainly via 2 routes. 1: The canonical
function of BCL-2 inhibits apoptosis by
preventing oligomerization of the pro-
apoptotic proteins BAX and BAK, which
otherwise can induce mitochondrial
outer membrane permeabilization
(MOMP). 2: BCL-2 facilitates the im-
port of the anti-oxidant glutathione and
complex IV subunits into the mi-
tochondria. This positively aﬀects the
mitochondrial membrane potential
(Δψ) and counteracts its drop to pre-
vent induction of the mitochondrial
permeability transition pore (MPTP).
(B) The processes of ﬁssion and mito-
phagy are tightly connected. Division
of mitochondria by ﬁssion involves the
GTPase DRP1 and the receptor FIS1,
and enables separation of dysfunctional
mitochondrial parts from healthy ones.
Dysfunctional parts are further de-
graded by mitophagy. Interference
with either BCL-2 functioning or mito-
phagy was shown to target LSCs.
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dependency. Interestingly, BCL-2 inhibition has been shown to impair
the viability of leukemic cells with diﬀerent backgrounds with regard to
karyotype abnormalities and molecular mutations (Carter et al., 2016;
Chan et al., 2015; Niu et al., 2014), indicating that LSCs have common
intrinsic characteristics. Resistance to BCL-2 inhibition was observed in
AMLs with high expression of the anti-apoptotic protein MCL-1, but
these AMLs were shown to be targeted by combined treatment with
BCL-2 and MCL-1 inhibitors (O’ Reilly et al., 2018; Pan et al., 2015;
Ramsey et al., 2018; Tron et al., 2018).
Paradoxically, certain leukemia-associated mutations can reinforce
an increased dependency of LSCs on anti-apoptotic proteins. For in-
stance, IDH1/2 mutants were shown to directly inhibit complex IV
activity, thereby lowering the mitochondrial activity and increasing the
dependency on apoptosis inhibitors such as BCL-2 in order to prevent
induction of cell death pathways triggered by a very low mitochondrial
membrane potential (Chan et al., 2015). A recent study aimed to
identify pathways whose interference might confer increased sensitivity
of AML cells to BCL-2 inhibition and identiﬁed several metabolic
pathways including OXPHOS, nucleotide biosynthesis and the heme
biosynthesis pathway (Lin et al., 2019). Mechanistically, heme deple-
tion triggered impaired function of the mitochondrial ETC and caused
lowering of mitochondrial membrane potential, thereby potentiating
Venetoclax-induced apoptosis. This ﬁnding supports the concept that
cells with low mitochondrial activity, such as LSCs, have an increased
dependency on anti-apoptotic pathways. Clinical trials have shown
promising results for treatment of relapsed/refractory AML when Ve-
netoclax was used as monotherapy (Konopleva et al., 2016), as well as
for newly-diagnosed, elderly AML patients when Venetoclax was used
in combination with hypomethylating agents (DiNardo et al., 2019).
However, Venetoclax-based treatment seems to work less eﬃciently in
relapsed patients compared to previously untreated patients (DiNardo
et al., 2018). Apparently, relapsed LSCs acquire diﬀerent metabolic
properties and fuel OXPHOS via diﬀerent routes, for instance by up-
regulation of fatty acid metabolism (Jones et al., 2018). Therefore, they
seem to be less dependent on BCL-2 for maintaining suﬃciently high
mitochondrial activity to ensure their survival.
8.2. Targeting autophagy to eradicate LSCs
Autophagy is an important strategy for avoiding accumulation of
damaged proteins and organelles that eventually can lead to cell death.
For leukemia cells, functional autophagy was found to be crucial for
leukemic transformation and for impairing cellular response to che-
motherapy (reviewed in (Auberger and Puissant, 2017)). High expres-
sion of genes involved in autophagy regulation was shown to be asso-
ciated with poor prognosis in AML (Nguyen et al., 2019b), and several
recent studies have suggested autophagy inhibition as a potential
strategy for targeting LSCs (Folkerts et al., 2017; Jang et al., 2017; Pei
et al., 2018). ROS-low CD34+ AMLs were shown to have higher basal
levels of autophagy and increased sensitivity to autophagy compared to
their ROS-high CD34+ counterparts (Folkerts et al., 2017). Pei et al.
(2018) identiﬁed factors that are expressed diﬀerently in ROS-low AML
LSCs compared to the ROS-high non-LSC fraction and reported a crucial
role of the mitophagy-related protein FIS1 (mitochondrial ﬁssion pro-
tein 1), which highlights the importance of mitochondrial dynamics for
LSC maintenance (Fig. 3B). Knockdown of FIS1 was shown to severely
impair the stem and progenitor potential of AML LSCs, but not of
normal HSCs (Pei et al., 2018), and AML patients with a high FIS1
expression were less likely to respond to chemotherapy (Tian et al.,
2014). Similarly, increased activation of the ﬁssion protein DRP1 in T-
ALL cells by bone marrow-niche mediated stimuli was shown to lower
ROS levels, change the mitochondrial phenotype to a more fragmented
morphology and improve chemoresistance (Cai et al., 2016). Recently,
it was shown that overexpression of the vacuole membrane protein
(VMP1), a putative autophagy protein, results in reduced Venetoclax-
sensitivity of CD34+ AML cells (Folkerts et al., 2019). These data
indicate that high levels of autophagy can contribute to the character-
istic features of LSCs. However, the regulation of autophagy is complex
and its role in leukemia development and maintenance not yet fully
understood, and might also depend on the mutational background.
Inhibition of autophagy in normal HSCs was associated with accumu-
lation of mitochondrial ROS, DNA damage and activation of the Notch
signaling pathway that impairs normal HSC diﬀerentiation, which
might be beneﬁcial for AML development (Cao et al., 2015). In line
with this, heterozygous loss of the key-autophagy gene Atg5 in an MLL-
ENL model for AML enhanced disease progression and aggressiveness
(Watson et al., 2015). Additionally, the fusion oncoproteins PML-RARA
and BCR-ABL were shown to be degraded by autophagy, and activation
of autophagy is part of treatment-strategies for leukemias with these
genetic alterations (Torgersen and Simonsen, 2013). In summary, these
data highlight context-dependent roles of autophagy in leukemia.
9. Do ROS-low LCS drive AML relapse after chemotherapy?
Chemotherapy of AML patients frequently includes treatment with
the pyrimidine nucleoside analog cytarabine in combination with an-
thracyclines. While this strategy can lead to an initial reduction of
leukemic blasts in the majority of patients, the 5-year overall survival
rate of patients< 60 years has not signiﬁcantly improved in recent
decades and ranges from 35% to 40% (Dohner et al., 2015). Adverse
outcomes of AML are mainly associated with leukemia relapse, which is
assumed to be driven by LSCs that are not targeted by chemotherapy
and retain their disease-initiating properties (Shlush et al., 2017). This
model is supported by the increasing knowledge about characteristic
ROS-low LSC properties, since features such as low metabolic activity,
increased BCL-2 expression and high levels of autophagy can confer
increased chemotherapy resistance as described above. Additionally,
our group recently observed increased expression of the drug eﬄux
transporter ABCB1 in the ROS-low deﬁned LSC compartment (un-
published results), and high expression of ABC transporters in leukemia
cells has been linked to poor treatment outcome in AML patients (de
Jonge-Peeters et al., 2007; van der Kolk et al., 2000). Moreover, several
longitudinal sequencing studies have strongly supported the concept
that relapse is driven by a resistant cell population that is already
present prior to chemotherapy treatment, and is not generated as a
consequence of the mutagenic properties of the chemotherapeutic drugs
(Bachas et al., 2012; Ding et al., 2012; Parkin et al., 2013; Shlush et al.,
2017). However, it has not been shown that the ROS-low LSC popula-
tion drives disease relapse. The promising results of clinical trials in
which standard treatments were combined with Venetoclax are thought
to be a result of eﬃcient targeting of the ROS-low LSC population
(Pollyea and Jordan, 2019), and therefore support the hypothesis that
ROS-low LSCs drive disease recurrence after conventional che-
motherapy. However, other studies reported that chemoresistant cells
have features distinct from those of ROS-low cells: (Farge et al., 2017)
showed that the AML cells that persist after chemotherapy treatment
using cytarabine for 5 days have increased mitochondrial mass, mi-
tochondrial membrane potential and ROS production – and thus have
features somewhat opposite to ROS-low LSCs. Furthermore, other stu-
dies reported that treatment with cytarabine does not enrich for func-
tional LSCs (Griessinger et al., 2014) and eﬃciently targets the
CD34+CD38− cell population (Boyd et al., 2018). Notably, our group
recently observed that ROS-low LSCs are enriched for CD34+CD38−
cells (unpublished results), indicating that metabolic LSC character-
istics do overlap with previously described phenotypic LSC features
such as CD34/CD38 expression (Lapidot et al., 1994). These conﬂicting
reports on the characteristics of chemoresistant cells can likely be ex-
plained by diﬀerences between steady-state LSCs and LSCs that were
exposed to chemotherapy. LSCs have been shown to undergo pheno-
typic changes during the course of chemotherapy (Ho et al., 2016), and
this might also apply to their metabolic characteristics. Consequently,
LSCs with low ROS levels could be indeed the cell population that is
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most resistant to chemotherapeutic drugs, but they might respond to
the severe therapy-related stress with upregulation (transient or
otherwise) of their mitochondrial activity.
10. Conclusion
Cellular ROS levels inversely correlate with the functionality of both
normal stem cells and leukemic stem cells. Low ROS levels apparently
reﬂect a metabolic state of relatively low mitochondrial activity, which
coincides with the low mitochondrial membrane potential, low levels of
cellular ATP and the small, fragmented mitochondria morphology
found in both HSCs and LSCs. Avoiding accumulation of ROS and
maintaining mitochondrial stability is essential for both types of stem
cells in order to prevent ROS-mediated cell damage and induction of
cell death pathways mediated by mitochondrial dysfunction. Multiple
gene knockout studies have demonstrated that targeting metabolic
pathways such as glycolysis and oxidative phosphorylation, or redox-
regulating machineries such as autophagy and anti-oxidative enzymes,
interferes with stem cell maintenance. In steady-state, however, HSCs
and LSCs seem to rely on diﬀerent strategies to maintain their char-
acteristic ROS-low condition. HSCs reside in a hypoxic bone marrow
niche and preferentially use glycolysis for their energy generation,
which results in reduced ROS production compared to ATP production
by mitochondrial oxidative phosphorylation. In contrast, LSCs rely
strongly on their remaining mitochondrial activity, which they main-
tain through mitophagy and mechanisms dependent on the anti-apop-
totic protein and master regulator of mitochondrial activity BCL-2. The
strong dependency of LSCs on BCL-2 and certain key players in mito-
phagy seems to be a characteristic feature of LSCs, and is not observed
to this extent in normal HSCs or in the total mononuclear AML cell
population. Therefore, interference with those pathways is a promising
strategy for eradicating LSCs, which are apparently not eﬃciently tar-
geted by standard chemotherapy approaches.
An interesting question that has not been completely answered is
whether the higher ROS levels observed in the total leukemia cell po-
pulation compared to ROS-low LSCs have a causative role in reducing
stemness potential, or if they are simply a reﬂection of a diﬀerent
metabolic state that is not compatible with stem cell function. A recent
study showed that standard induction chemotherapy leads to elevation
of ROS, but does not eﬃciently target LSCs, indicating that increased
ROS levels alone are not suﬃcient to compromise LSC viability or
function (Pollyea et al., 2018a). To improve current therapy protocols,
future studies should continue to investigate the metabolic properties of
LSCs and shed light on this question.
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